Ovcon: profile and news

Wilson Bayly Holmes - Ovcon Ltd - Dealings in Securities Apr 25, 2006
WBH Wilson Bayly Holmes - Ovcon Ltd - Dealings in Securities Wilson Bayly Holmes - Ovcon Ltd (Incorporated in the Republic of South Africa) (Registration ... - Finance24,

Warner Chilcott Reports Operating Results for the Quarter ended ... May 15, 2006
OVCON(R) net sales in the quarter increased a modest $1.2 million (+5.3%) as the growth in prescription demand compared with the prior year slowed following ... - PR Newswire (press release),

Around the Markets: Africa gets an early lift from soccer May 9, 2006
She owns shares of Aveng and Iliad, as well as Murray & Roberts and Wilson Bayly Holmes-Ovcon, which operates in building contracting, civil engineering, roads ... - International Herald Tribune,

Grinaker, WBHO awarded R175m commercial development contract Apr 24, 2006
Building contractor Grinaker-LTA, in joint venture with Wilson Bayly Holmes Ovcon, has been awarded an R715-million contract for a new office development in ... - Engineering News (press release),

Other information

Indication
For treatment of moderate to severe vasomotor symptoms associated with the menopause, female hypogonadism, prostatic carcinoma-palliative therapy of advanced disease, breast cancer, as an oral contraceptive, and as emergency contraceptive.

Pharmacology
Ethinyl estradiol is a synthetic derivative of the natural estrogen estradiol. It is one of two estrogens currently used in oral contraceptive pills. The other, mestranol, is converted to ethinyl estradiol before it is biologically active. Ethinyl estradiol and norethindrone are used together as an oral contraceptive agent.

Mechanism Of Action
Estrogens diffuse into their target cells and interact with a protein receptor. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Estrogens increase the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and suppress follicle-stimulating hormone (FSH) from the anterior pituitary. The combination of an estrogen with a progestin suppresses the hypothalamic-pituitary system, decreasing the secretion of gonadotropin-releasing hormone (GnRH).

Drug Category
Estrogens; ATC:G03CA01

Brand Names/Synonyms
17?-Ethynylestradiol; 17alpha-Ethinylestradiol; 17alpha-Ethynylestradiol; 17alpha-Ethynyloestradiol; Aethinyloestradiolum; Aethinyoestradiol [German]; Alesse; Alora; Amenoron; Amenorone; Anovlar; BRN 2419975; Binovum; Brevicon; Brevinor; CCRIS 286; CHEMBANK1139; Climara; Conceplan; Cyclosa; Demulen; Desogen; Dicromil; Diognat-E; Diogyn E; Diogyn-E; Diprol; Dyloform; EE; EE2; EO; ETHINYLESTRADIOL; Ertonyl; Esclim; Esteed; Estigyn; Estinyl; Eston-E; Estopherol; Estoral; Estoral {[Orion]}; Estorals; Estrace; Estraderm; Estradiol; Estring; Estrogel; Estrogen; Ethidol; Ethinoral; Ethinyl Estradiol; Ethinyl-Oestranol; Ethinylestradiolum [Inn-Latin]; Ethinylestriol; Ethinyloestradiol; Ethy 11; Ethynylestradiol; Ethynyloestradiol; Eticyclin; Eticyclol; Eticylol; Etinestrol; Etinestryl; Etinilestradiol [Inn-Spanish]; Etinilestradiolo [Dcit]; Etinoestryl; Etistradiol; Etivex; Feminone; Fempatch; Follicoral; Genora; Ginestrene; Gynodiol; Gynolett; HSDB 3587; Halodrin; Inestra; Innofem; Jenest; Kolpolyn; Levlen; Linoral; Lo/Ovral; Loestrin; Logynon; Lynoral; Marvelon; Menolyn; Menostar; Mercilon; Microfollin; Microgynon; Mircette; Modicon; NEE; NSC-10973; Necon; Nelova; Neo-Estrone; Neocon; Nogest-S; Norcept; Nordette; Norethin 1/35 E; Norimin; Norinyl; Norlestrin; Novestrol; Oradiol; Orestralyn; Orestrayln; Ortho Tri-Cyclen; Ortho-Cept; Ortho-Cyclen; Ortho-Novum; Ovcon; Ovex; Oviol; Ovral; Ovran; Ovranette; Ovysmen; Palonyl; Perovex; Primogyn; Primogyn C; Primogyn M; Progynon C; Progynon M; Prosexol; Spanestrin; Stediril; Synphase; Tetragynon; Thiuram E; Thiuranide; Tri-Levlen; Tri-Norinyl; Trinordiol; Trinovum; Triphasil; Vagifem; Varnoline; Vivelle; Ylestrol

Dosage Forms
DISC (SUSTAINED-RELEASE); GEL; IMPLANT; LIQUID; PATCH; RING (SLOW-RELEASE); SOLUTION; TABLET

Absorption
Rapid and complete absorption follows oral intake of ethinyl estradiol (bioavailability 43%).

Interactions
Drug Interactions for Ethinyl Estradiol:

Certain endocrine and liver function tests may be affected by estrogen-containing oral contraceptives. The following similar changes may be expected with larger doses of estrogen:

Increased sulfobromophthalein retention; increased prothrombin and factors VII, VIII, IX, and X; decreased antithrombin 3; increased norepinephrine-induced platel et aggregation; increased thyroid binding globulin (TBG) leading to increased circulating total thyroid hormone, as measured by PBI, T₄ by column, or T₄ by radioimmunoassay. Free T₃ resin uptake is decreased, reflecting the elevated TBG; free T₄ concentration is unaltered: impaired glucose tolerance; decreased pregnanediol excretion; reduced response to metyrapone test; reduced serum folate concentration; increased serum triglyceride and phospholipid concentration.

Chemical IUPAC Name
17-ethynyl-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol

Chemical Formula
C20H24O2

Half Life
36 +/- 13 hours

Drug Type
Approved Drug

# Accession No
APRD00691

CAS Registry Number
57-63-6